Ken Griffin’s Liminatus Pharma LIMN Stock Holding History

Ken Griffin’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$116K	Buy	677,518 +606,588	+855%	+$323K	﹤0.01%	11885
2025 Q4	$43.3K	Buy	+70,930	New	+$78.8K	﹤0.01%	12100

Other funds holding LIMN

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPIM

Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ken Griffin's LIMN Position: Q1 2026 in Review

Ken Griffin increased its Liminatus Pharma (LIMN) stake by 855% in Q1 2026, buying an estimated $323K and bringing the position to 677,518 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #11885.

Ken Griffin first reported a position in LIMN in Q4 2025 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold LIMN as of Q1 2026.

Ken Griffin held 677,518 shares of Liminatus Pharma worth $116K as of Q1 2026.
Ken Griffin bought 606,588 Liminatus Pharma shares in Q1 2026, an estimated $323K.
Liminatus Pharma made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #11885 holding.
Ken Griffin first reported a position in Liminatus Pharma in Q4 2025 and has held it in 2 quarters since.
15 funds tracked by Wall St. Rank held Liminatus Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.